Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Overexpressing Gastric Carcinoma”

12 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 12 of 12 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06492317
What this trial is testing

RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer

Who this might be right for
HER2-positive Gastric Cancer
The First Affiliated Hospital of Zhengzhou University 20
Early research (Phase 1)Looking for participantsNCT06253871
What this trial is testing

A Phase 1/1b Study of IAM1363 in HER2 Cancers

Who this might be right for
HER2 Mutation-Related TumorsHER2HER2-positive Breast Cancer+10 more
Iambic Therapeutics, Inc 243
Large-scale testing (Phase 3)UnknownNCT04714190
What this trial is testing

RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Who this might be right for
Gastric CancerHER2 Overexpressing Gastric Carcinoma
RemeGen Co., Ltd. 351
Testing effectiveness (Phase 2)Study completedNCT02795988
What this trial is testing

IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer

Who this might be right for
Gastrointestinal NeoplasmsAdenocarcinoma
Imugene Limited 64
Testing effectiveness (Phase 2)Looking for participantsNCT06109467
What this trial is testing

Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer

Who this might be right for
GastroEsophageal CancerGastric Cancer
H. Lee Moffitt Cancer Center and Research Institute 36
Not applicableStudy completedNCT04181333
What this trial is testing

Safety and Efficacy of Trastuzumab BS

Who this might be right for
Gastric Cancer
Pfizer 8
Early research (Phase 1)Study completedNCT01602406
What this trial is testing

Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer

Who this might be right for
Advanced HER2-positive Breast Cancer or Gastric Cancer
Novartis Pharmaceuticals 64
Early research (Phase 1)Study completedNCT01598077
What this trial is testing

A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer

Who this might be right for
HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell CarcinomaHER2 + Breast CancerHER2 + Gastric Cancer+2 more
Novartis Pharmaceuticals 54
Early research (Phase 1)Study completedNCT01649271
What this trial is testing

Phase I Trial of Afatinib and Trastuzumab in HER2 Overexpressing Cancer.

Who this might be right for
Breast NeoplasmsStomach Neoplasms
Boehringer Ingelheim 13
Early research (Phase 1)Active Not RecruitingNCT04660929
What this trial is testing

CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors

Who this might be right for
HER2-positiveAdenocarcinomaBile Duct Cancer+28 more
Carisma Therapeutics Inc 48
Testing effectiveness (Phase 2)Study completedNCT03556345
What this trial is testing

RC48-ADC in Local Advanced or Metastatic Gastric Cancer Subjects With the Overexpression of HER2

Who this might be right for
Gastric CancerHER2 Overexpressing Gastric Carcinoma
RemeGen Co., Ltd. 127
Large-scale testing (Phase 3)Active Not RecruitingNCT05002127
What this trial is testing

Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)

Who this might be right for
Gastric CancerGastroesophageal Junction AdenocarcinomaGastric Adenocarcinoma
ALX Oncology Inc. 127